Brought to you by 
Axcan licenses Abbott's gastrointestinal drug Itax
24 Jan 2005
Executive Summary
Gastroenterology specialist Axcan Pharma has received exclusive rights to develop, manufacture, and market Abbott Laboratories' patented Itax (itopride hydrochloride) in North America, Latin America, and EU countries including the UK, France, Germany, Italy, and Spain.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Axcan licenses Abbott's gastrointestinal drug Itax
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice